Hospitalisations related to nervous-system diseases in Australia, 1998-2019: a secular trend analysis.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
27 09 2023
Historique:
medline: 29 9 2023
pubmed: 28 9 2023
entrez: 27 9 2023
Statut: epublish

Résumé

The burden of neurological disease-related disabilities and deaths is one of the most serious issues globally. We aimed to examine the hospitalisation profile related to nervous system diseases in Australia for the duration between 1998 and 2019. A secular trend analysis using a population-based dataset. This analysis used a population-based study of hospitalised patients in Australia. Hospitalisation data were extracted from the National Hospital Morbidity Database, which collects sets of episode-level information for Australian patients admitted to all private and public hospitals. All patients who were hospitalised in all private and public hospitalisations. Hospitalisation rates related to nervous system diseases. Hospitalisation rates increased by 1.04 times (from 650.36 (95% CI 646.73 to 654.00) in 1998 to 1328.90 (95% CI 1324.44 to 1333.35) in 2019 per 100 000 persons, p<0.01). Overnight-stay episodes accounted for 57.0% of the total number of hospitalisations. Rates of the same-day hospitalisation for diseases of the nervous system increased by 2.10-fold (from 219.74 (95% CI 217.63 to 221.86) in 1998 to 680.23 (95% CI 677.03 to 683.43) in 2019 per 100 000 persons). Rates of overnight-stay hospital admission increased by 42.7% (from 430.62 (95% CI 427.66 to 433.58) in 1998 to 614.70 (95% CI 611.66 to 617.75) in 2019 per 100 000 persons). 'Episodic and paroxysmal disorders' were the most prevalent reason for hospitalisation, which accounted for 49.0% of the total number of episodes. Female hospitalisation rates increased by 1.13-fold (from 618.23 (95% CI 613.24 to 623.22) in 1998 to 1316.33 (95% CI 1310.07 to 1322.58) in 2019 per 100 000 persons). Male hospitalisation rates increased by 86.4% (from 682.95 (95% CI 677.67 to 688.23) in 1998 to 1273.18 (95% CI 1266.98 to 1279.37) in 2019 per 100 000 persons). Hospitalisation rates for neurological disorders in Australia are high, potentially owing to the ageing of the population. Males had greater rates of hospitalisation than females.

Identifiants

pubmed: 37758673
pii: bmjopen-2023-074553
doi: 10.1136/bmjopen-2023-074553
pmc: PMC10537858
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e074553

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Neurosci J. 2016;2016:2827090
pubmed: 27314003
Front Neurol. 2021 Aug 02;12:674114
pubmed: 34408720
Pediatr Crit Care Med. 2013 Oct;14(8):801-10
pubmed: 23842588
Int J Mol Sci. 2020 May 20;21(10):
pubmed: 32443735
Int J Popul Data Sci. 2018 May 17;3(1):421
pubmed: 32935002
Heart Fail Rev. 2021 Sep;26(5):1063-1080
pubmed: 32338334
Diabetes Metab Syndr Obes. 2013;6:57-78
pubmed: 23467255
Lancet Neurol. 2020 Mar;19(3):255-265
pubmed: 31813850
BMJ Open. 2021 Aug 25;11(8):e051844
pubmed: 34433611
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
Ann Emerg Med. 1996 Apr;27(4):485-9
pubmed: 8604867
Saudi Med J. 2017 Dec;38(12):1173-1180
pubmed: 29209664
Zhonghua Nei Ke Za Zhi. 2014 Mar;53(3):202-5
pubmed: 24767208
Sens Int. 2021;2:100117
pubmed: 34806053
Organization (Lond). 2023 Jan;30(1):193-209
pubmed: 37038431
Endocrine. 2006 Apr;29(2):243-56
pubmed: 16785600
Expert Rev Neurother. 2019 Sep;19(9):807-822
pubmed: 31353980
PLoS Med. 2012 Jan;9(1):e1001158
pubmed: 22272190
Dtsch Arztebl Int. 2018 Feb 9;115(6):83-90
pubmed: 29478436
Aust J Rural Health. 2019 Aug;27(4):272-274
pubmed: 31429135
Int J Gen Med. 2012;5:255-63
pubmed: 22505823
Healthcare (Basel). 2022 Sep 01;10(9):
pubmed: 36141282

Auteurs

Sawsan Ma Abuhamdah (SM)

Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan s.abuhamdah@ju.edu.jo.
Department of Pharmaceutical Sciences, Al Ain University College of Pharmacy, Abu Dhabi, UAE.

Abdallah Y Naser (AY)

Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Isra University, Amman, Jordan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH